课件：胃肠胰神经内分泌肿瘤.ppt

* * * This open-label, multicenter phase II study assessed the clinical activity of the mTOR inhibitor everolimus, alone or in combination with octreotide LAR, in patients with metastatic pNET who experienced progression on or after chemotherapy Eligible patients were ?18 years of age with histologically confirmed, well to moderately differentiated, advanced (unresectable or metastatic) pNET with progressive disease documented by RECIST during or after cytotoxic chemotherapy, a World Health Organization (WHO) performance status ?2, and adequate bone marrow, hepatic, and renal function Patients